Featured News
Next-Generation Sequencing: New Hope for Cancer Patients
Accelerating Safer, Personalized Treatment
For cancer patients and their families, every breakthrough brings new hope. In an exciting development, we’ve partnered with Singapore General Hospital (SGH) to accelerate the development of Next-Generation CAR-T cell therapy, a promising approach that uses the body’s own immune system to fight cancer.
SGH is pioneering the use of cord blood-derived allogeneic CAR-T cells, offering a potentially life-saving option for patients in need. To support this effort, we will provide state-of-the-art master cell banking (MCB) and Next-Generation sequencing (NGS) testing, ensuring these therapies meet the highest standards of safety, quality, and effectiveness.
This collaboration is focused on delivering faster innovation, safer treatments, and a more personalized approach to cancer care. NGS technology is revolutionizing how cell therapies are tested, offering more precise and reliable results compared to traditional methods. With this cutting-edge approach, SGH can bring novel cancer treatments to clinical trials more quickly, giving patients access to potentially life-saving therapies sooner because every moment matters.